文献速递头颈外科

生物肿瘤标志物(maspin、CD105、nm23-H1)与喉癌疾病复发:聚类分析

Biological tumor markers (maspin, CD105, nm23-H1) and disease relapse in laryngeal cancer: cluster analysis.
PubMed 文献 · Head Neck · 2020-03-25

该研究旨在探讨一组生物标志物(maspin、CD105和nm23-H1)能否将喉鳞状细胞癌(LSCC)患者分层为同质的疾病复发风险聚类。结论建议在前瞻性临床试验中测试类似的生物变量组合,以确定对高风险复发患者进行更积极治疗是否能显著改善其复发率和/或疾病特异性生存。

要点

  • 聚类分析基于nm23-H1、CD105和maspin免疫组化表达可将LSCC患者分为七个同质复发风险聚类。

核心结论

  • 基于maspin、CD105和nm23-H1的聚类分析可识别LSCC患者中不同复发风险的同质聚类。

研究设计与样本

  • 对89例喉鳞状细胞癌(LSCC)患者进行回顾性聚类分析,依据nm23-H1、CD105和maspin的免疫组化表达进行分类。

主要发现

  • 分析识别出七个同质聚类。

临床怎么用

  • 该生物标志物组合经聚类分析识别的风险分层,需在前瞻性临床试验中验证是否能指导更积极治疗以改善高风险患者的复发率和/或疾病特异性生存。

局限性

  • 研究为回顾性设计,样本量有限(89例),结论需前瞻性临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this investigation was to see if a panel of biomarkers (maspin, CD105, and nm23-H1) could be used to stratify patients with laryngeal squamous cell carcinoma (LSCC) in homogeneous disease recurrence risk clusters. METHODS: Cluster analysis was used to classify 89 patients based on their immunohistochemical expression of nm23-H1, CD105, and maspin. RESULTS: Our analysis identified seven homogeneous clusters: the LSCC recurrence rate was lowest in cluster 6 (non-nuclear maspin pattern, nuclear nm23-H1 expression ≥10%, endothelial CD105 expression <6%; P = .009), and highest in cluster 3 (non-nuclear maspin pattern, nuclear nm23-H1 expression <10%, endothelial CD105 expression ≥6%; P <.001). CONCLUSIONS: Similar panels of biological variables identified by cluster analysis should be tested in prospective clinical trials to establish whether treating patients identified as being at higher risk of LSCC recurrence more aggressively could significantly improve their recurrence rate and/or disease-specific survival.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Franz L, Tealdo G, Contro G, et al. Biological tumor markers (maspin, CD105, nm23-H1) and disease relapse in laryngeal cancer: cluster analysis. Head Neck. 2020. PMID: 32212364. doi:10.1002/hed.26152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。